pharmaceuticals

Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.

Supreme Court's decision to review the controversial bankruptcy deal involving the maker of Oxycontin means the settlement will remain on hold at least through December.

The FDA granted approval of Zurzuvae for adults experiencing severe depression related to childbirth or pregnancy. The pill is taken once a day for 14 days.

The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors.

The crabs are drained of some of their blood and returned to the environment, yet some inevitably die. Regulators say revisions to guidelines for handling the animals should keep more alive through the process.

The company says its factory near Rocky Mount, North Carolina, makes nearly 25% of Pfizer's sterile injectable medicines used in U.S. hospitals

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.

Victims of prescription opioid addiction as well as communities slammed by the opioid crisis could wind up with nothing if Mallinckrodt files for a second bankruptcy.

The drugmaker is seeking to halt the program, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years.